***Background.*** Antimicrobial resistance among uropathogens is a global problem with limited therapeutic alternatives. The Urinary Tract Infection Drug Resistance Index (UTI-DRI) in the South-Atlantic Region of the United States has steadily increased in the last decade by 60% (baseline 16.9 in 1999 to 27.1 in 2010). Fosfomycin is a broad-spectrum antimicrobial that has attracted interest for the treatment of lower UTIs caused by Gram-negative uropathogens resistant to commonly used antimicrobials. Data regarding antimicrobial susceptibilities for *Enterobacteriaceae*in the United States are extremely scarce.

***Methods.*** Retrospective review of urines cultures performed at Integrated Regional Laboratories (IRL) serving 14 acute care (ACF) and 5 long-term care facilities (LTCF) in South Florida between January 2013 and December 2013. Urine cultures were from hospitalized patients, emergency departments and residents in LTCF. Only *Enterobacteriaceae* isolates that tested non-susceptible to extended spectrum beta-lactam agents were included in the analysis. Isolates were considered to be ESBL-producing if they were intermediate (I), susceptible dose-dependent (SDD), or resistant (R) to any 3rd or 4th generation cephalosporin per the 2013 Clinical Laboratory Standards Institute (CLSI) breakpoints. Fosfomycin Kirby-Bauer disk diffusion susceptibilities were determined with a 200 ug disk using 2014 CLSI breakpoints: \>16 S, 13-15 I, \<12 R.

***Results.*** ESBL-producing *Enterobacteriaciae* from 290 ACF and 87 LTCF urine cultures were analyzed. The number of *E. coli* isolates ranged from 3-35 in ACF and 2-40 in LTCF. 93% of isolates in ACF and 97% in LTCF were susceptible (Table). *Klebsiell*a and *Proteus* strains were less susceptible than *E. coli*strains.

###### 

Number and percent of urinary isolates susceptible to fosfomycin

  Species           ACF             LTCF
  ----------------- --------------- -------------
  *E. coli*         202/209 (97%)   75/76 (99%)
  *K. pneumoniae*   60/70 (86%)     9/10 (90%)
  *K. oxytoca*      4/4 (100%)      No data
  *P. mirabilis*    5/7 (71%)       0/1 (0%)
  All               271/290 (93%)   84/87 (97%)

***Conclusion.*** Fosfomycin has excellent in vitro activity against urinary ESBL-producing *Enterobacteriacea* strains, especially *E. coli*, in South Florida acute and long-term care facilities.
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